Alvotech and STADA Launch Hukyndra (biosimilar, adalimumab) in Switzerland
Shots:
- Alvotech & STADA launch Hukyndra, a biosimilar to Humira (adalimumab) & marketed by Spirig HealthCare AG, STADA’s subsidiary in Switzerland
- Hukyndra is a high-concentration, low-volume, citrate-free formulation that is available in 80mg/0.8mL & 40mg/0.4mL in a self-administration safety device & 40mg/0.4mL in a pre-filled auto-inject pen. Under the collaboration with STADA, Alvotech’s strength will use for biosimilars development & manufacturing platform to broaden patient access to cost-effective biologics across the EU
- Hukyndra was approved in the EU & other countries as Simlandi & is under review in multiple countries, incl. the US. The collaboration b/w Alvotech & STADA in the EU includes Hukyndra & 6 biosimilar candidates across autoimmunity & other indications
Ref: Globenewswire | Image: Alvotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
